Stock Analysis

These Analysts Think UpHealth, Inc.'s (NYSE:UPH) Sales Are Under Threat

Source: Shutterstock

The analysts covering UpHealth, Inc. (NYSE:UPH) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.

Following the downgrade, the latest consensus from UpHealth's three analysts is for revenues of US$238m in 2022, which would reflect a major 140% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$275m in 2022. It looks like forecasts have become a fair bit less optimistic on UpHealth, given the substantial drop in revenue estimates.

See our latest analysis for UpHealth

NYSE:UPH Earnings and Revenue Growth March 31st 2022

The Bottom Line

The clear low-light was that analysts slashing their revenue forecasts for UpHealth next year. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on UpHealth after today.

But wait - there's more! We have estimates for UpHealth from its three analysts out until 2023, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

Valuation is complex, but we're helping make it simple.

Find out whether UpHealth is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.